Changes after publication
December 2014: minor maintenance.
February 2014: implementation section updated to clarify human growth hormone (somatropin) is recommended as an option for treating growth failure in children. Additional minor maintenance update also carried out.
March 2012: minor maintenance.
A minor correction was made to section 6.1 of the guidance in July 2010. This does not affect the funding direction, which applies from the original date of publication in May 2010.